Zacks Research upgraded shares of Alterity Therapeutics (NASDAQ:ATHE – Free Report) to a hold rating in a report released on Wednesday,Zacks.com reports.
Several other research firms have also issued reports on ATHE. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Monday, April 20th. LADENBURG THALM/SH SH assumed coverage on shares of Alterity Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $10.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.00.
Get Our Latest Report on Alterity Therapeutics
Alterity Therapeutics Price Performance
Hedge Funds Weigh In On Alterity Therapeutics
An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC acquired a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.25% of Alterity Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.14% of the company’s stock.
About Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.
Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.
Recommended Stories
- Five stocks we like better than Alterity Therapeutics
- How to Invest in the Biggest European Defense Surge in Decades
- The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
